A scientific study on Mritasanjeevana Rasa - an Ayurvedic medicine

A Comparative Pharmaceutico-Analytical and Clinical study of Mritasanjeevana Rasa and its modified formulation on Amavata (Rheumatoid Arthritis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024876

Enrollment

Registered

2020-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: MRM: Mritasanjeevana Rasa Modified (MRM) Dose â?? 125 mg BD Dosage form â?? Pills Mode of administration â?? Oral Duration â?? 28 days Anupana â?? Water Control Intervention1: MRC: Mrit

Eligibility

Inclusion criteria

Inclusion criteria: Patients present with classical signs & symptoms of Amavata. Patients willing to give informed consent to participate for 28 days.

Exclusion criteria

Exclusion criteria: Patients present with systemic diseases like Diabetes mellitus, Cardiac Disease, Hypertension, etc. Patients on prolonged ( > 6 weeks) medication with corticosteroids, etc. or any other drugs that may have an impact on the outcome of the study Pregnant/lactating mother

Design outcomes

Primary

Measure	Time frame
Alteration in Disease Activity Score (DAS28)Timepoint: 28 days	—

Secondary

Measure	Time frame
Changes in signs and symptomsTimepoint: 28 days	—

Countries

India

Contacts

Public ContactDrVarad Charkha

National institute of Ayurveda

moharpalmeena73@gmail.com9414564382

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026